# US 2025/0082746 A1 · Circular rna vaccines against sars-cov-2 variants and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082746 A1
- Document ID: US20250082746A1
- Status: Published application
- Kind: A1
- Application number: 18/727,308
- Filed: 2023-01-09
- Published: 2025-03-13
- Earliest claimed: 2022-01-11
- Assignees: Peking University
- Applicants: Peking University
- Inventors: Wensheng WEI; Liang QU; Zongyi YI; Yong SHEN; Liangru LIN; Feng CHEN
- Web page: https://patentgrep.com/patent/US20250082746A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2795/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2840/203: having an IRES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are circular RNAs (circRNAs) encoding an antigenic polypeptide of a SARS-CoV-2 variant. Provided are circRNA vaccines against a SARS-CoV-2 variant, such as a Delta or Omicron variant. The circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike(S) protein or a fragment thereof of a SRAS-CoV-2 variant. Also provided are methods of treating or preventing a SARS-CoV-2 infection using the circRNAs or compositions thereof.

## Claims

### Claim 1

A circular RNA (circRNA) comprising a nucleic acid sequence encoding an antigenic polypeptide of a SARS-CoV-2 variant, wherein the SARS-CoV-2 variant is a Delta variant or an Omicron variant.

### Claim 2 (depends on 1)

The circRNA of claim 1, wherein the antigenic polypeptide comprises a Spike(S) protein or a fragment thereof of the SARS-CoV-2 variant.

### Claim 3 (depends on 2)

The circRNA of claim 2, wherein the antigenic polypeptide comprises a receptor-binding domain (RBD) of the S protein.

### Claim 4 (depends on 3)

The circRNA of claim 3, wherein the RBD comprises amino acid residues 319 to 542 of a full-length S protein of SARS-CoV-2, wherein the numbering is based on SEQ ID NO: 1.

### Claim 5 (depends on 3)

The circRNA of claim 3, wherein the SARS-CoV-2 variant is a Delta variant, and wherein the antigenic polypeptide comprises the amino acid sequence of SEQ ID NO: 18.

### Claim 6 (depends on 3)

The circRNA of claim 3, wherein the SARS-CoV-2 variant is an Omicron variant, and wherein the antigenic polypeptide comprises the amino acid sequence of SEQ ID NO: 19.

### Claim 7 (depends on 1)

The circRNA of claim 1, wherein the antigenic polypeptide further comprises a multimerization domain.

### Claim 8 (depends on 7)

The circRNA of claim 7, wherein the multimerization domain is a C-terminal Foldon (Fd) domain of a T4 fibritin protein that mediates trimerization of the T4 fibritin protein.

### Claim 9 (depends on 8)

The circRNA of claim 8, wherein the Fd domain comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 10 (depends on 1)

The circRNA of claim 1, further comprising a Kozak sequence operably linked to the nucleic acid sequence encoding the antigenic polypeptide.

### Claim 11 (depends on 1)

The circRNA of claim 1, further comprising an in-frame 2A peptide coding sequence operably linked to the 3′ end of the nucleic acid sequence encoding the antigenic polypeptide.

### Claim 12 (depends on 1)

The circRNA of claim 1, further comprising an internal ribosomal entry site (IRES) sequence operably linked to the nucleic acid sequence encoding the antigenic polypeptide.

### Claim at position 13

-14. (canceled)

### Claim 15 (depends on 12)

The circRNA of claim 12, further comprising a polyAC or polyA sequence disposed at the 5′ end of the IRES sequence.

### Claim 16 (depends on 1)

The circRNA of claim 1, further comprising an m6A modification motif sequence operably linked to the nucleic acid sequence encoding the antigenic polypeptide.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The circRNA of claim 1, further comprising a 3′ exon sequence recognizable by a 3′ catalytic Group I intron fragment flanking the 5′ end of the nucleic acid sequence encoding the antigenic polypeptide, and a 5′ exon sequence recognizable by a 5′ catalytic Group I intron fragment flanking the 3′ end of the nucleic acid sequence encoding the antigenic polypeptide.

### Claim 19 (depends on 1)

A composition comprising a plurality of circRNAs of claim 1, wherein the antigenic polypeptides corresponding to the plurality of circRNAs are different with respect to each other.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A circRNA vaccine comprising the circRNA of claim 1.

### Claim at position 21

-25. (canceled)

### Claim 26 (depends on 1)

A method of treating or preventing a SARS-CoV-2 infection in an individual, comprising administering to the individual an effective amount of the circRNA of claim 1.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The method of claim 26, wherein the SARS-CoV-2 infection is caused by a Delta or Omicron variant of SARS-CoV-2.

### Claim at position 25

-31. (canceled)

### Claim 32 (depends on 1)

A linear RNA capable of forming the circRNA of claim 1.

### Claim 33 (depends on 32)

A nucleic acid construct comprising a nucleic acid sequence encoding the linear RNA of claim 32, optionally comprising a T7 promoter operably linked to the nucleic acid sequence.
